Kymab
E422485
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Kymab canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T4221592 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Kymab Context triple: [Cambridge life sciences ecosystem, hasKeyCompany, Kymab]
-
A.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
B.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
C.
Immunix
Immunix was a security-focused software company known for developing Linux security technologies, including the precursor to the AppArmor mandatory access control system.
-
D.
Behring
Behring is a German surname most notably associated with Emil Adolf von Behring, the pioneering physiologist and first Nobel laureate in Physiology or Medicine for his work on serum therapy.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Kymab Target entity description: Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
A.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
B.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
C.
Immunix
Immunix was a security-focused software company known for developing Linux security technologies, including the precursor to the AppArmor mandatory access control system.
-
D.
Behring
Behring is a German surname most notably associated with Emil Adolf von Behring, the pioneering physiologist and first Nobel laureate in Physiology or Medicine for his work on serum therapy.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
Statements (30)
| Predicate | Object |
|---|---|
| instanceOf | biotechnology company ⓘ |
| basedIn | Cambridge, United Kingdom NERFINISHED ⓘ |
| country | United Kingdom ⓘ |
| develops |
antibody therapeutics
ⓘ
biologic drugs ⓘ |
| field |
immunology
ⓘ
therapeutic antibodies ⓘ |
| focusesOn | antibody-based therapeutics ⓘ |
| goal | treatment of human diseases with antibody therapeutics ⓘ |
| hasBusinessModel | drug discovery and development ⓘ |
| hasRAndDActivity |
clinical development of antibody drugs
ⓘ
preclinical drug discovery ⓘ |
| headquartersLocation | Cambridge, United Kingdom NERFINISHED ⓘ |
| industry |
biopharmaceuticals
ⓘ
biotechnology ⓘ |
| locationCity | Cambridge NERFINISHED ⓘ |
| locationCountry | United Kingdom ⓘ |
| operatesInSector |
life sciences
ⓘ
pharmaceutical research ⓘ |
| platformType | transgenic mouse platform ⓘ |
| productType |
biopharmaceutical products
ⓘ
therapeutic antibodies ⓘ |
| researchArea |
human therapeutic antibodies
ⓘ
monoclonal antibodies ⓘ |
| specializesIn |
antibody discovery
ⓘ
antibody engineering ⓘ |
| technologyType | transgenic animal platform ⓘ |
| usesMethod |
in vivo antibody generation
ⓘ
transgenic mouse immunization ⓘ |
| usesTechnology | proprietary transgenic mouse platforms ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Kymab Description of subject: Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.